Company intelligence / Profile preview

Huaxia Sangsheng Pharmaceutical

Beijing, Beijing Shi, Chinachictr.org.cn ↗

Ownership: Private
Development stage: Other

Overview

Huaxia Shengsheng Pharmaceutical focuses on the research and development of small molecule drugs targeting nervous system diseases, neoplasms, and endocrine/metabolic disorders. Its lead program for ALS has reached Phase 1 clinical trials. Other programs are in preclinical stages. No detailed clinical results are publicly available as of March 2025[1].

Therapeutic areas: NeurologyOncologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Huaxia Sangsheng Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huaxia Sangsheng Pharmaceutical.

Explore the full profile